Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Clinical Trials

Completely Resected EGFR Mutant Non-Small Cell Lung Cancer Treatment Study

Randomized double blind placebo controlled study of erlotinib or placebo in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC).

Drug Treatment Study for Patients with Advanced Cancers

A phase 1/1b, open-label, multicenter, repeat-dose, dose-selection study of CPI-444 as single agent and in combination With atezolizumab in patients with selected incurable cancers.

Investigational Drug Treatment Study for Patients with Lung Cancer

An open label, dose-finding and proof of concept study of the PD-L1 Probody™ therapeutic, CX-072, as monotherapy and in combination with Yervoy® (ipilimumab) or with Zelboraf® (vemurafenib) in subjects with advanced or recurrent solid tumors or lymphomas

Radiation Therapy Treatment Study for Patients with Limited-Stage Small Cell Lung Cancer

Phase III comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin and etoposide.

Surgically Resected ALK-Positive Early Stage Non-Small Cell Lung Cancer Treatment Study

A phase II double-blind trial for surgically resected early stage non-small cell lung cancer: Crizotinib versus placebo for patients with tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein.

The ADAURA Study

The ADAURA study.

Treatment Study for Patients with Advanced Malignancies

A phase 1, open-label, dose-escalation study of SEA-CD40 in adult patients with advanced malignancies.

Treatment Study for Patients with Advanced Solid Tumor Malignancies

Phase 1/1b study of MGCD516 in patients with advanced solid tumor malignancies.

Treatment Study for Patients with EGFR Mutation and ALK Positive Non-Small Cell Lung Cancer

Phase II multi-center study of pembrolizumab in combination with platinum-based doublet chemotherapy in patients with EGFR mutation and ALK positive non-small cell lung cancer with progressive disease following prior tyrosine kinase inhibitors (TKIs).

Treatment Study for Patients with Non-Small Cell Lung Cancer, Melanoma or Colorectal Cancer

A phase 1b/2, open-label, dose escalation study of entinostat in combination with pembrolizumab in patients with non-small cell lung cancer, with expansion cohorts in patients with NSCLC, melanoma, and mismatch repair-proficient colorectal cancer.

Pages